Ernexa Therapeutics Inc.

ERNA·NasdaqCM·Healthcare
Compare
1.9900−0.0300 (−1.49%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close2.0200
Open1.9800
Day range1.94002.0400
52-week range1.840046.0000
Off day high−2.45%
Off 52-week high−95.67%
Volume17.27K
Avg. volume (3M)48.35K
Market cap3.25M
EPS (TTM)-13.63
Forward P/E-0.21
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)2.74
Shares outstanding1.63M
Short interest1.66% of float
Earnings dateAug 11, 2025 (est.)
Analyst target30.0000
Profit margin0.00%

Against its peers

Compare in full ›
ERNA XBIO AIM NCEL IMNN CELZ
Market cap 3.25M 4.71M 6.42M 14.79M 5.09M 4.95M
P/E (TTM) — — — 4.9 — —
Forward P/E -0.2 -3.0 -0.4 -4.3 -0.5 -0.7
Price/book 0.7 0.8 0.6 2.3 2.2 0.5
Dividend yield — — — — — —
1-year change −95.10% −26.10% −90.12% −38.31% −77.02% −78.05%
Today −1.49% −3.37% +0.19% −3.03% +0.78% −3.21%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All ERNA news ›
The Manila Times··2 outlets

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

The Manila Times Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology un

More from 1 other outlet
Quiver Quantitative··2 outletsPositive

Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk at Next-Generation Cancer Therapeutics Meeting for Preclinical Ovarian Cancer Data

Ernexa Therapeutics announced preclinical data for ERNA-101, highlighting its promise in ovarian cancer treatments, at a major conference. ERNA-101 is Ernexa’s lead cell therapy program aimed at treating advanced ovarian cancer by…

More from 1 other outlet

From the 4Search news index, newest first.

In the news

9mentions in 30 days
9with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance